Wound healing

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant Treatment of haemophilia B, 26/10/2018 Withdrawn

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Brain, Disease, Coagulation, Patient, Committee, Knowledge, Internal, Regulation, Haemophilia, EMA, IRIS, Joint, Human, Wound healing, Clinical trial, European, Therapy, COMP, Bleeding, Spinal cord, Sponsor, European Commission, Immune system, Antibody, Safety, Factor IX, Blood, Marketing, Limited, Haemophilia B, Medicine, Pharmaceutical industry

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant Treatment of haemophilia B, 26/10/2018 Withdrawn

Key Points: 


Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant Treatment of haemophilia B, 26/10/2018 Withdrawn

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Pressure, Cell, Disease, Risk, Patient, Committee, Knowledge, Regulation, Cancer, EMA, IRIS, Scar, Eye, Wound healing, European, Allergic conjunctivitis, COMP, Collagen, Skin, European Commission, Safety, Glaucoma, Sclera, Pharmaceutical industry

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Key Points: 


Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Uni-Bio Science Group Announces 2023 Annual Results

Retrieved on: 
Wednesday, April 10, 2024
Escherichia coli, Gel, Prevalence, FN, Hip, Risk, Patient, Janet Woodcock, EGF, KL1, Yoy, Wound healing, Osteoporosis, CMO, Marketing, Dry eye syndrome, Government, Wrist, Genetic engineering, Ageing, Ophthalmology, Fine chemical

[27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).

Key Points: 
  • [27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).
  • The Group reached a significant milestone with the successful introduction of Skbrella™ FN, marking its entry into the advanced skincare raw material market.
  • In 2023, the Group recorded a revenue of approximately HK$484.7 million, representing an increase of 10.1 % YoY.
  • The Group strictly controlled its general and administrative expenses, which only accounted for 9.8% of revenue in 2023 as compared with 10.7% in 2022.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Fibroblast, EGFR, Warfarin necrosis, Risk, Communication, IL-6, Form, Diabetic foot ulcer, Conditional sentence, Patient, Research, Mouse, Gamma ray, Trial of the century, HDF, Hyperglycemia, Acceleration, Wound healing, Cytokine, Therapy, Cellular senescence, Interleukin, VEGF, Pharmaceutical industry

These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.

Key Points: 
  • These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
  • Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally.
  • FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
  • "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja.

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Wednesday, March 27, 2024
De novo, DFU, Diabetic foot ulcer, Certification, Burn, Government, Development, FY, MDAI, Patient, Research, History, Artificial intelligence, Classification, Sale, Standard of care, Human services, Research and development, Wound healing, Trial of the century, Clinical trial, ASPR, ISO, FDA, Administration, Food, Pharmaceutical industry

DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.

Key Points: 
  • DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
  • “Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer.
  • “
    In September 2023, we were awarded the largest contract in our history from the US Government valued at up to $150.0 million.
  • All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.

Bestqool Unveils the Key to Optimal Health: The Perfect Duration for Red Light Therapy Sessions

Retrieved on: 
Tuesday, March 26, 2024
Pigment, Health, Radiation, Burns, Fibromyalgia, Cell, Inflammation, Patient, Tissue, Muscle fatigue, Athlete, Arthritis, Light, Wound healing, Skin, Safety, Red light, Low-level laser therapy, Ageing, Medical imaging

Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.

Key Points: 
  • Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.
  • This revelation promises to enhance the efficacy and safety of Red Light Therapy, a popular and effective treatment that has captivated global attention for its numerous health benefits.
  • How Long Should Red Light Therapy Sessions Last?
  • In pain relief, Red Light therapy duration can last as long as 15 to 30 minutes instead.

Orphan designation: fidanacogene elaparvovec Treatment of haemophilia B, 19/11/2018 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Brain, Disease, Coagulation, Patient, Committee, Knowledge, Internal, Regulation, Haemophilia, EMA, IRIS, Joint, Human, Wound healing, European, COMP, Bleeding, Spinal cord, Antibody, Sponsor, European Commission, Immune system, Safety, Factor IX, Blood, Marketing, Haemophilia B, Medicine, Pharmaceutical industry

Orphan designation: fidanacogene elaparvovec Treatment of haemophilia B, 19/11/2018 Withdrawn

Key Points: 


Orphan designation: fidanacogene elaparvovec Treatment of haemophilia B, 19/11/2018 Withdrawn

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

Retrieved on: 
Wednesday, March 20, 2024
Cell adhesion, Ulcer, Wound, Partnership, Patient, Trauma, Surgeon, Wound healing, Collagen, Surgery

Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.

Key Points: 
  • Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.
  • As we have stated, one of our strategic priorities is to augment our best-in-class placental-derived product portfolio with xenografts and/or synthetic skin substitutes in order to meet the needs of a greater number of customers, domestically and abroad.
  • The collagen in this product serves as a dressing that allows for cell adhesion and migration into the wound site and supports wound healing.
  • “Additionally, we look forward to partnering with Regenity and leveraging their expertise to bring other products in our pipeline to market in the future.

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

Retrieved on: 
Wednesday, March 20, 2024
Burn, Patient, Matrix, Sale, Hernia, Human, Surgeon, Wound healing

MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc .

Key Points: 
  • MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc .
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the sale of its distribution rights related to NIVIS Fibrillar Collagen Pack to Atlanta-based MiMedx Group, Inc. (“MIMEDX”).
  • NIVIS is an absorbent collagen matrix indicated for the management of moderately to heavily exudating wounds and to control minor bleeding.
  • MIMEDX is a pioneer and leader focused on helping humans heal, with a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare.